证券代码：603858 证券简称：步长制药 公告编号：2025-064 山东步长制药股份有限公司 第五届董事会第二十次（年度）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十次（年 度）会议的通知于 2025 年 4 月 15 日发出，会议于 2025 年 4 月 25 日下午 13 时 以通讯方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主 持。会议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法 规及《山东步长制药股份有限公司章程》的相关规定，合法有效。 经与会董事研究，会议审议通过了如下议案： 1、《关于公司 2024 年度董事会工作报告的议案》 根据《中华人民共和国公司法》及《山东步长制药股份有限公司章程》的相 关规定，为总结公司董事会 2024 年度的工作情况，董事会编制了《山东步长制 药股份有限公司 2024 年度董事会工作报告》。 该议案尚需提交股东会审议。 表决结果：同意 9 票，反对 0 票，弃权 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-066 山东步长制药股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案及情况说明 经信永中和会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 山东步长制药股份有限公司（以下简称"公司"）母公司期末未分配利润为人民 币 5,365,632,450.38 元，2024 年度公司实现归属于上市公司股东的净利润为人 民币-553,797,938.80 元。经董事会决议，本次利润分配方案如下： 公司 2024 年度拟不派发现金红利，不进行资本公积金转增股本，不送红股。 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简称 "《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 本次利润分配方案尚须提交公司股东会审议批准。 （二）是否可能触及其他风险警示情形 单位：元 | 项目 | | ...

| 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 步长(香港)控股有限公司 | 49095.72 | 44.39 | 不变 | | 首诚国际(香港)有限公司 | 8274.24 | 7.48 | 不变 | | 山东步长制药（603858）股份有限公司回购专用 | 4485.36 | 4.06 | 不变 | | 刘少鸾 | 2645.90 | 2.39 | 不变 | | 杨伟 | 2203.01 | 1.99 | 不变 | | 西藏丹红企业管理有限公司 | 2040.84 | 1.85 | 不变 | | 蓝色经济区产业投资基金(有限合伙) | 1034.28 | 0.94 | 不变 | | 黄定旺 | 977.97 | 0.88 | 4.44 | | 香港中央结算有限公司 | 843.56 | 0.76 | -25.28 | | 南方中证500ETF | 773.51 | 0.70 | -25.00 | | 较上个报告期退出前十大股东有 | | | | | 苏州联胜化学有限公司 | 690.60 | 0.62 | 退出 | ...

山东步长制药股份有限公司 关于变更回购股份用途并注销暨减少注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603858 证券简称：步长制药 公告编号：2025-075 山东步长制药股份有限公司（以下简称"公司"）于2025年4月25日召开第五届董 事会第二十次（年度）会议及第五届监事会第五次（年度）会议，审议通过了《关于 变更回购股份用途并注销暨减少注册资本的议案》，公司拟将存放于公司回购专用证 券账户的44,853,573股股份用途变更为"减少公司注册资本"，并按照《中华人民共 和国公司法》《中华人民共和国证券法》及《上海证券交易所上市公司自律监管指引 第7号——回购股份》等相关规定进行注销，并按相关规定办理注销手续。 本次变更回购股份用途并注销暨减少注册资本事项尚需提交公司股东会审议。现 将有关事项公告如下： 一、回购股份方案及实施情况 公司于 2023 年 12 月 13 日召开第四届董事会第四十七次会议，审议通过了《关于 1 变更回购股份用途：公司拟将2023年回购方案的回购股 ...

山东步长制药股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/12/27 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 √用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 6,620,630股 | | 累计已回购股数占总股本比例 | 0.60% | | 累计已回购金额 | 9,803.75万元 | | 实际回购价格区间 | 13.86元/股~15.07元/股 | 证券代码：603858 证券简称：步长制药 公告编号：2025-080 一、回购股份的基本情况 山东步长制药股份有限公司（以下简称"公司"）于 2024 年 12 月 26 日召开 第五届董事会第十一次会议，审议通过了《关于以集中竞价交易方式回购股份的 方 ...

Financial Performance - In 2024, the company reported a net profit attributable to shareholders of negative value, leading to a decision not to distribute cash dividends or increase capital reserves[6]. - The company's operating revenue for 2024 was CNY 11,005,794,900.15, a decrease of 16.91% compared to CNY 13,245,133,303.78 in 2023[23]. - The net profit attributable to shareholders was -CNY 553,797,938.80 in 2024, representing a decline of 273.62% from CNY 318,973,324.80 in 2023[23]. - The basic earnings per share for 2024 was -CNY 0.5110, down 277.18% from CNY 0.2884 in 2023[24]. - The company reported a net cash flow from operating activities of CNY 939,950,568.92 in 2024, a significant recovery from -CNY 195,605,226.23 in 2023[23]. - The total assets at the end of 2024 were CNY 19,328,509,108.36, a decrease of 7.48% from CNY 20,892,297,542.28 at the end of 2023[23]. - The company’s weighted average return on equity was -5.07% in 2024, a decrease of 7.73 percentage points from 2.66% in 2023[24]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[154]. - The company reported a total revenue of 1.4 billion RMB for the fiscal year 2024, reflecting a year-on-year growth of 15%[159]. - The company reported a net loss attributable to ordinary shareholders of approximately 553.8 million RMB for the most recent fiscal year[189]. Shareholder Actions - The total amount spent on share repurchases was CNY 710,527,866.30, with plans to cancel the repurchased shares after shareholder approval[6]. - The cumulative cash dividend amount over the last three fiscal years was approximately 1.1974 billion RMB[191]. - The total amount for share repurchases and cancellations over the last three fiscal years was approximately 933.99 million RMB[191]. - The total cash dividend and share repurchase amount over the last three fiscal years reached approximately 2.1314 billion RMB[191]. - The company's retained earnings at the end of the most recent fiscal year were approximately 5.3656 billion RMB[191]. Risk Management - The company has outlined various risks in its operations, including industry and management risks, which are detailed in the management discussion section[8]. - The company has a comprehensive risk management strategy in place to address potential operational challenges[8]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity of the annual report[8]. - The company faces risks related to drug price reductions due to national policy influences, which may compress profit margins[140]. Research and Development - The company applied for 35 new patents in 2024 and successfully obtained 27 patents, including 9 invention patents[34]. - The company is developing 12 biological products targeting major diseases such as tumors and osteoporosis, with some products entering the NDA application stage[35]. - The company has a diverse pipeline of products under development, focusing on major disease areas such as cardiovascular, gynecology, diabetes, malignant tumors, digestive, and respiratory systems[62]. - The company is actively engaged in vaccine research and development, with multiple products in various stages, including flu and meningococcal vaccines[60]. - The company is enhancing its understanding and investment in biopharmaceuticals, with plans to complete the production base in Luzhou, Sichuan[131]. - The company has established a research and development model that combines independent innovation with external technical cooperation, enhancing its technological capabilities[101]. - The company is focusing on research and development of new products and technologies to drive future growth[150]. Market Strategy - The company aims to leverage clinical data to validate product efficacy and enhance market reputation, thereby driving sales growth[33]. - The company aims to establish a comprehensive health industry chain, including investments in medical devices, cosmetics, disinfectants, health products, and health foods[35]. - The company is actively expanding into various therapeutic areas, including gynecology, urology, diabetes, and malignant tumors, while leveraging its traditional strengths in traditional Chinese medicine[53]. - The company is focused on integrating traditional Chinese medicine with modern pharmaceutical processes to enhance treatment efficacy[35]. - The company plans to enhance its marketing budget by 25% to support new product launches and brand awareness initiatives[156]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB earmarked for this purpose[154]. Governance and Compliance - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report[3]. - The company has established a governance structure compliant with relevant laws and regulations, ensuring independent operation of its board and management[147]. - The company is committed to strict compliance with legal regulations and internal guidelines in all committee activities[173][174][175]. - The company is revising its internal governance documents, including the Articles of Association and decision-making rules for related transactions[165]. - The company has proposed to revise its articles of association and governance rules to enhance operational efficiency and compliance[150]. Employee and Talent Management - The total number of employees in the parent company is 1,735, while the total number of employees in major subsidiaries is 5,954, resulting in a combined total of 7,689 employees[180]. - The company has established effective talent introduction and training mechanisms to enhance its innovation capabilities[36]. - The training plan includes establishing a talent growth platform, multi-level training based on employee roles, and integrating training assessments into performance evaluations[183]. - The company emphasizes a fair salary policy based on external and internal equity, market principles, strategic orientation, and economic principles[182]. Environmental Responsibility - The company invested approximately 8.6791 million RMB in environmental protection during the reporting period[198]. - The total annual discharge of chemical oxygen demand from the factory was 41.6 tons, with a concentration of 91.1 mg/L[199]. - The total annual discharge of ammonia nitrogen was 0.1892 tons, with a concentration of 0.408 mg/L[199].

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,784,946,981.48, representing a 5.47% increase compared to ¥2,640,556,945.44 in the same period last year[3]. - Net profit attributable to shareholders increased by 169.49% to ¥307,261,088.17 from ¥114,015,551.69 year-on-year[3]. - Net profit for Q1 2025 was ¥289,890,204.09, significantly up from ¥87,698,871.86 in Q1 2024, representing a growth of 230.5%[16]. - Basic and diluted earnings per share rose by 180.10% to ¥0.2899 from ¥0.1035 in the same period last year[3]. - Earnings per share for Q1 2025 was ¥0.2899, compared to ¥0.1035 in Q1 2024, reflecting a substantial increase[16]. Cash Flow - The net cash flow from operating activities surged by 814.82% to ¥678,016,314.81, up from ¥74,114,961.92 in the previous year[3]. - Cash flow from operating activities for Q1 2025 was ¥678,016,314.81, a significant increase from ¥74,114,961.92 in Q1 2024, representing a growth of approximately 815.5%[20]. - Total cash inflow from operating activities in Q1 2025 reached ¥2,992,606,467.80, compared to ¥2,749,269,900.40 in Q1 2024, indicating an increase of about 8.8%[20]. - The total cash inflow from operating activities was primarily driven by an increase in cash received from sales, which amounted to ¥2,929,463,148.12 in Q1 2025, compared to ¥2,649,327,706.77 in Q1 2024[20]. - The company reported a decrease in cash paid for goods and services, which was ¥526,854,643.76 in Q1 2025, down from ¥636,791,962.37 in Q1 2024, indicating a reduction of approximately 17.3%[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥19,836,965,205.27, a 2.63% increase from ¥19,328,509,108.36 at the end of the previous year[3]. - Total current assets increased to ¥8,090,878,234.09 as of March 31, 2025, up from ¥7,537,198,596.50 at the end of 2024[11]. - Total liabilities rose to ¥9,786,024,120.20 as of March 31, 2025, compared to ¥9,520,425,198.24 at the end of 2024[12]. - The company reported a total asset value of ¥19,836,965,205.27 as of March 31, 2025, an increase from ¥19,328,509,108.36 at the end of 2024[12]. - The company’s total equity increased to ¥10,050,941,085.07 as of March 31, 2025, up from ¥9,808,083,910.12 at the end of 2024[12]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.53% to ¥10,475,032,314.12 from ¥10,216,464,921.09[3]. - The weighted average return on equity increased by 1.99 percentage points to 2.97%[3]. Non-Recurring Items - The company reported non-recurring gains and losses totaling ¥7,672,820.13 for the period[5]. Strategic Developments - The increase in net profit was primarily driven by higher sales volume and changes in product sales structure, along with the acquisition of Tonghua Guhong Pharmaceutical Co., Ltd.[6]. - The company has not disclosed any new product or technology developments, market expansion, or merger and acquisition strategies in this report[10]. Cash Flow from Investing and Financing Activities - Cash outflow from investing activities in Q1 2025 was ¥339,677,008.39, a substantial rise from ¥87,326,830.66 in Q1 2024, reflecting an increase of approximately 288.5%[20]. - Net cash flow from investing activities for Q1 2025 was -¥336,787,235.62, worsening from -¥86,404,964.15 in Q1 2024[20]. - Cash inflow from financing activities in Q1 2025 totaled ¥683,395,102.72, down from ¥950,358,691.77 in Q1 2024, a decrease of about 28.1%[20]. - Net cash flow from financing activities for Q1 2025 was ¥272,065,937.17, compared to ¥332,495,910.56 in Q1 2024, showing a decline of approximately 18.2%[20]. Accounting Standards - The company did not apply new accounting standards for the first time in 2025, as stated in the announcement[21].

关于山东步长制药股份有限公司 2024 年度营业收入扣除情况的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 2024 年度营业收入扣除情况表 | 1 | 关于山东步长制药股份有限公司 2024 年度营业收入扣除情况的专项说明 XYZH/2025CDAA9B0010 山东步长制药股份有限公司 根据《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指南 第 2 号业务办理》（以下简称营业收入扣除）相关规定，公司编制了后附的山东步长制 药股份有限公司 2024 年度营业收入扣除情况表（以下简称营业收入扣除情况表）。 按照营业收入扣除的相关规定编制和披露营业收入扣除情况表，并保证其合规性、 真实性、准确性及完整性是山东步长制药公司的责任。 我们对营业收入扣除情况表所载信息与我们审计山东步长制药公司2024年度财务 报表时所检查的会计资料和经审计的财务报表的相关内容进行核对，在所有重大方面没 有发现不一致。 为了更好地理解山东步长制药公司营业收入及其扣除情况，营业收入扣除情况表应 当与已审计的财务报表一并阅读。 1 专项说明（续） XYZH/2025CD ...

本资产评估报告依据中国资产评估准则编制 山东步长制药股份有限公司拟对收购浙江华派 生物医药有限公司股权形成的商誉进行减值测 试涉及的资产组可收回金额资产评估报告 沪众评报字〔2025〕第 0242 号 (共1册,第1册) 上海众华资产评估有限公司 2025年04月21日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 3131020020202500469 | | | --- | --- | --- | | 合同编号: | 25-众G-000071 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 沪众评报字(2025) 第0242号 | | | 报告名称: | 山东步长制药股份有限公司拟对收购浙江华派生物医药有限公司 股权形成的商誉进行减值测试涉及的资产组 可收回金额资产评估 报告 | | | 评估结论: | 550,000.000.00元 | | | 评估报告日: | 2025年04月21日 | | | 评估机构名称: | 上海众华资产评估有限公司 | | | 签名人员: | (资产评估师) 钱进 | 正式会员 编号: 31000017 | | | 俞慈航 ...

中信证券股份有限公司关于山东步长制药股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为山东步长 制药股份有限公司（以下简称"步长制药"或"公司"）首次公开发行股票并上市 的持续督导保荐人，根据《上海证券交易所股票上市规则》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司 募集资金管理和使用的监管要求》（2022 年修订）等法律、法规、规范性文件以 及《山东步长制药股份有限公司章程》（以下简称"《公司章程》"）《山东步长 制药股份有限公司募集资金管理制度》（以下简称"《募集资金管理制度》"）等 有关规定，对步长制药 2024 年度募集资金的存放和使用情况进行了专项核查，核 查情况如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准山东步长制药股份有限公司首次公开发 行股票的批复》（证监许可[2016]2385 号）核准，本公司向社会公开发行人民币普 通股股票（A 股）6,980 万股（每股面值 1 元）。截至 2016 年 11 月 ...